Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Beyond Air ( (XAIR) ).
On September 8, 2025, Beyond Air‘s subsidiary, NeuroNOS, received Orphan Drug Designation from the FDA for its investigational therapy, BA-101, aimed at treating Glioblastoma, a highly aggressive brain cancer. This designation highlights the company’s commitment to addressing rare neurological conditions and marks its entry into oncology, offering potential market exclusivity and incentives for further development.
The most recent analyst rating on (XAIR) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Beyond Air stock, see the XAIR Stock Forecast page.
Spark’s Take on XAIR Stock
According to Spark, TipRanks’ AI Analyst, XAIR is a Neutral.
Beyond Air’s stock score is primarily influenced by its financial performance challenges, including negative profitability and cash flow issues. While the earnings call and corporate events provide some optimism with revenue growth and strategic initiatives, the technical analysis and valuation remain weak, reflecting bearish momentum and ongoing losses.
To see Spark’s full report on XAIR stock, click here.
More about Beyond Air
Beyond Air is a commercial stage medical device and biopharmaceutical company focused on utilizing Nitric Oxide (NO) for treating respiratory illnesses, neurological disorders, and solid tumors. The company has developed the LungFit® PH system for neonatal respiratory failure and is advancing other systems for severe lung infections. Beyond Air collaborates with The Hebrew University of Jerusalem for research on Autism Spectrum Disorder and other neurological conditions.
Average Trading Volume: 278,125
Technical Sentiment Signal: Strong Sell
Current Market Cap: $11.55M
For detailed information about XAIR stock, go to TipRanks’ Stock Analysis page.